About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Revolutionize Cancer Treatment with Oncolytic Virotherapies (OVs): Secure Access to Unrivaled Intelligence for Strategic Oncology Decisions - ResearchAndMarkets.com

The "Unlocking Opportunity: Dominate the Oncolytic Virotherapy Market with Confidence" directory has been added to ResearchAndMarkets.com's offering.

The world of oncolytic virotherapies (OVs) is transforming cancer treatment, unlocking new levels of precision, immune activation, and therapeutic potential. However, with rapid advancements, fierce competition, and an ever-expanding pipeline, staying ahead requires more than just insights - it demands up-to-date intelligence, strategic foresight, and data-driven decision-making.

In 2024/25 alone, the oncology pipeline saw a surge of innovation, with 22 new OVs, over 105 drugs with events, and 654 total events spanning 368 total drug programs - a clear signal of the accelerating pace and complexity in this space.

Introducing the Oncolytic Virotherapies Analytical Tool - your comprehensive solution to navigate this dynamic field, track emerging trends, and capitalize on groundbreaking opportunities.

The Ultimate Tool for Exploring What Makes This Field So Exciting

  • Tumor-selective replication - OVs are engineered to selectively infect and replicate in cancer cells while sparing normal tissue.
  • Dual mechanism of action - 1. Direct oncolysis (destruction of tumor cells) 2. Indirect immune activation via release of tumor antigens and danger signals.
  • Immune priming - Viral lysis converts "cold" tumors into "hot" ones by promoting immune cell infiltration and antigen presentation.
  • Gene delivery vehicles - OVs can be engineered to express therapeutic genes (e.g., cytokines, immune checkpoint inhibitors, bispecific T-cell engagers).
  • Synergy with other immunotherapies - Especially immune checkpoint inhibitors (ICIs), vaccines, and CAR-T therapies.
  • Intratumoral administration - Allows for high local activity with potentially reduced systemic toxicity.
  • Broad platform flexibility - Multiple virus families can be used (HSV, adenovirus, vaccinia, reovirus, measles, etc.), each with unique strengths.

The impact? A rapidly growing clinical pipeline, breakthrough FDA approvals, and a surge in investment opportunities - making the oncolytic virotherapy field one of the most exciting frontiers in oncology today.

6 Game-Changing Benefits for You

With the Oncolytic Virotherapies Analytical Tool you will:

  • Track the Competitive Landscape - monitor active organizations, new drugs, targets, and technologies
  • Accelerate Licensing & Partnerships - access top biotech developers, BD&L contacts, and academic projects
  • Power High-Impact Reports & Presentations - fuel data-driven decisions with near real-time market intelligence - all exportable in ready made graphs and tables.
  • Engage Key Opinion Leaders (KOLs) - connect with clinical and scientific experts shaping the field
  • Find the Right Investors - tap into a network of oncology-focused funding partners
  • Stay Ahead of Industry Events - analyze data from top global oncology conferences (AACR, ASCO, ESMO, ASH, and more)

Your Oncolytic Virotherapies Analytical Tool is never out of date thanks to continuous updates and monthly email alerts highlighting the latest developments in the field.

You will have thousands of drugs, targets, companies, clinical trials, deals and much more at your fingertips. See below for a breakdown of the near real-time coverage.

Support & Inspiration at Your Fingertips

Leverage expertise as your virtual business development team - ready when you are. The 24/7 support ensures help is always available, while a rich library of How-to Training Videos empowers you with proven best practices. From competitive pipeline analysis to real-world case studies submitted by fellow users, you'll find actionable insights designed to elevate your work.

A Tool That Grows With You

Unlike static reports that offer just a snapshot in time, these Analytical Tools provide a full year of online access - complete with near real time updates, new features, pipeline alerts, and dedicated support. When you're ready to go further, you can seamlessly renew your access or upgrade to the industry-leading full-service platform: 1stOncology - your comprehensive partner in oncology drug development.

System Requirements

  • Web-based application compatible with all major browsers: Chrome, Firefox, Safari, and Internet Explorer
  • Internet access

Secure Your Access to Unrivaled Intelligence for Strategic Decision-Making in Oncology Drug Development

This tool is powered by an award-winning, artificial intelligence (AI) enhanced intelligence platform with over 25 years of expertise in oncology, delivering uniquely comprehensive business, competitive and clinical intelligence across all stages of oncology drug development.

For business development and search & evaluation, it provides unmatched visibility into the global oncology landscape - spanning technologies, targets, start-ups to pharma, and academic-commercial opportunities - making it a powerful deal book with integrated licensing contacts and thousands of past deals.

In clinical development, the tool features an industry-leading biomarker intelligence panel of over 3,000 biomarkers and tracks their roles as stratifying, predictive, and pharmacodynamic markers, alongside companion diagnostic initiatives from early stage to approval. Proprietary early success/failure indicators spotlight clinical leaders and laggards, helping you monitor and anticipate shifts in the evolving landscape.

This clinical trial intelligence goes beyond endpoints, capturing dosage details, resistance mechanisms, adverse events, food effects, trial phase and status progression, first-in-human (FIH) studies, tumor stage/grade, and line of therapy (LoT) - offering a complete view of the trial landscape.

The publisher simplifies the complexity of combination therapy development, breaking down targets, drug modalities, indications, and trial stages to create a map of evolving strategies for fast, strategic decision-making.

Finally, the team integrated Real-World Evidence (RWE) with multi-point analytics tailored to any development stage. Whether segmented by drug modality, co-medication profiles, or biomarker clusters, the tool enables deep, contextual insights - driving faster, smarter, and evidence-based decisions in oncology research and development.

Coverage Breakdown from your Oncolytic Virotherapies Analytical Tool

Competitor Overview

  • Organizations Monitored: 270+

Organization Types:

  • Corporate: 197
  • Private: 121
  • Public: 59
  • Academic: 53
  • Startup: 12
  • Cancer Ctr/Hospital: 18
  • Big Pharma/Biotech: 17

Top 5 Drug Developers:

  • Transgene
  • Virogin Biotech
  • Akamis Bio
  • Boeringer Ingelheim
  • ImmVira

Top 5 Nations:

  • USA
  • China
  • South Korea
  • Germany
  • Japan

Pipeline

  • Total No Drugs: 360+
  • Discovery: 50
  • Preclinical: 220
  • Phase 1: 49
  • Phase 2: 38
  • Phase 3: 8
  • Pre-registration: 1
  • Marketed: 2
  • Target & Armor: 104
  • Tumor Types: 102
  • Clinical Trials: 293
  • Clinical Biomarkers: 136
  • Drugs in Combination Therapies: 50

Deals & Alliances

  • No. Deals (Last 5 Years): 48
  • BD&L Contacts: >400
  • World-Wide Academic Commercial Opportunity Projects: 5

Funding & Investors

  • Funding (Last 5 Years): >250
  • Top Investors: 107

For more information about this directory visit https://www.researchandmarkets.com/r/gfrr7t

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com



For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.